- Home
- MIRM vs QLYS Comparison
MIRM vs QLYS Comparison
Compare MIRM & QLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | QLYS |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 7.0B |
| IPO Year | 2019 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MIRM | QLYS |
|---|---|---|
| Price | $82.85 | $207.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 22 |
| Target Price | $153.07 | ★ $181.03 |
| AVG Volume (30 Days) | ★ 732.8K | 543.1K |
| Earning Date | 11-03-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.59 | 16.99 |
| EPS | N/A | ★ 2.91 |
| Revenue | $19,138,000.00 | ★ $321,607,000.00 |
| Revenue This Year | $33.62 | $9.85 |
| Revenue Next Year | $17.72 | $8.22 |
| P/E Ratio | ★ N/A | $67.69 |
| Revenue Growth | N/A | ★ 15.32 |
| 52 Week Low | $63.23 | $74.51 |
| 52 Week High | $130.00 | $206.25 |
Technical Indicators
Market Signals| Indicator | MIRM | QLYS |
|---|---|---|
| Relative Strength Index (RSI) | 43.12 | 62.90 |
| Support Level | $78.07 | $81.58 |
| Resistance Level | $88.31 | N/A |
| Average True Range (ATR) | 3.94 | 10.11 |
| MACD | 0.69 | 0.27 |
| Stochastic Oscillator | 46.34 | 94.01 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.